1. Home
  2. RCUS vs PHR Comparison

RCUS vs PHR Comparison

Compare RCUS & PHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCUS
  • PHR
  • Stock Information
  • Founded
  • RCUS 2015
  • PHR 2005
  • Country
  • RCUS United States
  • PHR United States
  • Employees
  • RCUS N/A
  • PHR N/A
  • Industry
  • RCUS Biotechnology: Pharmaceutical Preparations
  • PHR Business Services
  • Sector
  • RCUS Health Care
  • PHR Consumer Discretionary
  • Exchange
  • RCUS Nasdaq
  • PHR Nasdaq
  • Market Cap
  • RCUS 1.4B
  • PHR 1.4B
  • IPO Year
  • RCUS 2018
  • PHR 2019
  • Fundamental
  • Price
  • RCUS $15.52
  • PHR $24.01
  • Analyst Decision
  • RCUS Buy
  • PHR Strong Buy
  • Analyst Count
  • RCUS 12
  • PHR 13
  • Target Price
  • RCUS $34.50
  • PHR $29.38
  • AVG Volume (30 Days)
  • RCUS 755.7K
  • PHR 480.1K
  • Earning Date
  • RCUS 11-06-2024
  • PHR 12-09-2024
  • Dividend Yield
  • RCUS N/A
  • PHR N/A
  • EPS Growth
  • RCUS N/A
  • PHR N/A
  • EPS
  • RCUS N/A
  • PHR N/A
  • Revenue
  • RCUS $263,000,000.00
  • PHR $405,137,000.00
  • Revenue This Year
  • RCUS $127.13
  • PHR $18.78
  • Revenue Next Year
  • RCUS N/A
  • PHR $13.81
  • P/E Ratio
  • RCUS N/A
  • PHR N/A
  • Revenue Growth
  • RCUS 119.17
  • PHR 19.91
  • 52 Week Low
  • RCUS $13.52
  • PHR $17.07
  • 52 Week High
  • RCUS $20.31
  • PHR $29.16
  • Technical
  • Relative Strength Index (RSI)
  • RCUS 44.11
  • PHR 61.65
  • Support Level
  • RCUS $14.78
  • PHR $20.83
  • Resistance Level
  • RCUS $18.07
  • PHR $26.00
  • Average True Range (ATR)
  • RCUS 0.96
  • PHR 1.29
  • MACD
  • RCUS -0.16
  • PHR 0.33
  • Stochastic Oscillator
  • RCUS 22.32
  • PHR 64.90

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

About PHR Phreesia Inc.

Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.

Share on Social Networks: